NCT05177822View on ClinicalTrials.gov

Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure

PHASE2RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

May 24, 2022

Primary Completion Date

February 28, 2027

Study Completion Date

December 31, 2027

Conditions
Heart Failure
Interventions
DRUG

Anakinra

Anakinra 100 mg/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment;

OTHER

Placebo

0.9% NaCl/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment.

Trial Locations (2)

22908

RECRUITING

University of Virginia, Charlottesville

23298

RECRUITING

Virginia Commonwealth University, Richmond

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

University of Virginia

OTHER

lead

Virginia Commonwealth University

OTHER